Navigation Links
XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
Date:2/19/2009

MENLO PARK, Calif., Feb. 19 /PRNewswire-FirstCall/ -- XTENT, Inc. (Nasdaq: XTNT) today reported financial results for the fourth quarter and year ended December 31, 2008 and provided an update on its business.

The company reported a net loss of $7.1 million, or $0.31 per share, for the fourth quarter of 2008, compared to a net loss of $11.9 million, or $0.52 per share, for the fourth quarter of 2007. For the year ended December 31, 2008, XTENT had a net loss of $41.1 million, compared to $38.8 million for the same period last year. As of December 31, 2008, XTENT had cash, cash equivalents and short-term investments of $19.1 million.

Research and development expenses decreased to $5.3 million in the fourth quarter of 2008 from $9.2 million for the same period in 2007, primarily due to a decrease in expenditures for personnel, prototype parts and supplies as well as consulting and services and other costs incurred for clinical trials. General and administrative expenses were $2.0 million in the fourth quarter of 2008 versus $3.4 million for the same period in 2007, primarily due to a decrease in personnel, consulting, legal, and professional expenses. Research and development expenses for the year ended December 31, 2008 totaled $31.2 million, compared to $30.9 million for the same period last year. General and administrative expenses for the year ended December 31, 2008 totaled $10.9 million compared to $11.3 million for the same period in 2007.

On January 23, XTENT announced an initiative to reduce headcount by eliminating 115 positions, representing 94% of the Company's total workforce. The reduction is expected to be completed during March 2009. The Company expects to incur approximately $1.1 to $1.2 million in expenses in connection with this initiative, all of which are expected to be cash expenditures incurred in the first quarter of 2009.

Piper Jaffray & Co. has been engaged to help the company pursue strategic alternatives intended to maximize shareholder value which could include a sale of one or more of our non-core assets, such as our peripheral stent product or our bioabsorbable stent technology, a sale of all our assets or a merger.

About XTENT

XTENT, Inc. is a medical device company focused on developing and commercializing innovative customizable drug eluting stent (DES) systems for the treatment of coronary artery disease (CAD). CAD is the most common form of cardiovascular disease and the number one cause of death in the United States and Europe. XTENT(R) Custom NX(R) DES Systems are designed to enable the treatment of single lesions, long lesions and multiple lesions of varying lengths and diameters, in one or more arteries with a single device.

Note: XTENT(R) Custom NX(R) DES Systems have not been approved for sale by any regulatory authority.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this press release regarding XTENT's business that are not historical facts may be "forward-looking statements" that involve risks and uncertainties. Specifically, these statements include, but are not limited to those concerning: XTENT's expectations with respect to the timing and amount of any savings that may result from the company's cost reduction initiatives, the timing and amount of any expenses that may be incurred as a result of the company's headcount reduction and the potential for becoming a party to a strategic transaction. Forward-looking statements are based on management's current, preliminary expectations, and are subject to risks and uncertainties that could cause actual results to differ from the results predicted and which are included in the "Risk Factors" section of XTENT's most recent quarterly report on Form 10-Q for the quarter ended September 30, 2008. This quarterly report was filed with the SEC on November 12, 2008, and is available on the company's investor relations website at http://www.xtentinc.com and on the SEC's website at http://www.sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. XTENT undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.



                                 XTENT, INC.
                        (a development stage company)
                      Condensed Statements of Operations
             (unaudited; in thousands, except per share amounts)

                                        Three Months Ended      Year Ended
                                           December 31,        December 31,
                                          2008      2007      2008      2007
    Operating expenses:
      Research and development (1)       $5,252    $9,194   $31,170   $30,888
      General and administrative (1)      1,965     3,375    10,917    11,269
        Total operating expenses          7,217    12,569    42,087    42,157

    Loss from operations                 (7,217)  (12,569)  (42,087)  (42,157)

    Interest and other income, net          104       705       966     3,363

    Net loss                            $(7,113) $(11,864) $(41,121) $(38,794)

    Net loss per share - basic and
     diluted                             $(0.31)   $(0.52)   $(1.78)   $(1.87)

    Weighted-average common shares
     outstanding used in per share
     calculation                         23,294    22,790    23,116    20,703



    (1) Includes the following stock-
        based compensation charges:
         Research and development          $268      $460    $1,418    $1,490
         General and administrative        $496      $766    $2,435    $2,088



                                 XTENT, INC.
                        (a development stage company)
                           Condensed Balance Sheets
                          (unaudited, in thousands)

                                                 December 31,     December 31,
                                                     2008             2007
    Cash, cash equivalents and short term
     investments                                    $19,125         $57,760
    Working capital                                  17,070          54,581
    Total assets                                     23,995          62,415

    Deficit accumulated during the development
     stage                                         (133,981)        (92,860)
    Total stockholders' equity                       21,508          58,331

'/>"/>
SOURCE XTENT, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. XTENT Announces Third Quarter 2007 Financial Results
2. XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe
3. XTENT Announces 2007 Financial Results Conference Call
4. New study shows extent of harmful human influences on global ecosystems
5. XTENT Announces 2007 Financial Results
6. XTENT to Present at Cowen and Companys 28th Annual Health Care Conference
7. XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
8. XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
9. XTENT Announces Second Quarter 2008 Financial Results and Business Progress
10. XTENT Announces Third Quarter 2008 Financial Results
11. APIC Covers Up Extent and Causes of Deadly C. diff
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: